证券代码：301290 证券简称：东星医疗 公告编号：2025-028 江苏东星智慧医疗科技股份有限公司 关于召开公司2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年6月23日召 开了第四届董事会第十一次会议，审议通过了《关于提请召开2025年第一次临 时股东大会的议案》，董事会决定于2025年7月10日（星期四）下午2:30在公司 会议室召开2025年第一次临时股东大会。为了进一步保护投资者的合法权益， 方便公司股东行使表决权，本次股东大会将采用现场投票与网络投票相结合的 方式，根据有关规定，现将股东大会的相关事项通知如下： 一、会议召开基本情况 1、股东大会届次：2025年第一次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第十一次会议审议通过了 《关于提请召开2025年第一次临时股东大会的议案》，本次股东大会的召开符 合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和 《公司章程》的规定。 4、 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-026 一、监事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 6 月 23 日 14:00 在公司会议室以现场方式召开。本次会议通 知已于 2025 年 6 月 19 日通过邮件的方式送达全体监事。本次会议由监事会主席 朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会 议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 江苏东星智慧医疗科技股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于部分募投项目终止的议案》 经审议，监事会认为：公司本次终止部分募投项目的事项，是结合募投项目 的投资进度和实际建设情况，经审慎评估后作出的决定，不存在损害公司及股东 利益的情形，不会对公司的正常生产经营产生不利影响，符合公司长期发展规划 和全体股东的利益。本次 ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-025 江苏东星智慧医疗科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第十 一次会议于 2025 年 6 月 23 日 8:45 在公司会议室以现场结合通讯的方式召开。 本次会议通知已于 2025 年 6 月 19 日通过邮件的方式送达全体董事。本次会议应 出席董事 7 人，实际出席董事 7 人，其中独立董事沈世娟女士、朱旗先生、上官 俊杰先生以通讯方式出席会议。会议由董事长万世平先生召集并主持，公司监事、 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《公司 法》等有关法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 （一）审议通过《关于部分募投项目终止的议案》 公司对首次公开发行股票募投项目"孜航医疗器械零部件智能制造及扩产项 目"予以终止，上述募投项目终止后，公司将该项目节余募集资金继续留存于其 专户进行管理。 公司保荐人出 ...

Group 1 - Company Gongchuang Turf (605099.SH) stated that the impact of domestic football events on its operations and performance is minimal, as its main business of artificial turf has a low revenue contribution from domestic sports grass [1] - Company Anglikang (002940.SZ) confirmed that its innovative drug project ALK-N001 is still in Phase I clinical trials, indicating a long R&D cycle and significant investment [2] - Company Yiwei Lithium Energy (300014.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image [3] Group 2 - Company Chaohongji (002345.SZ) also intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and improve competitiveness [4] - Company Dexin Technology (603032.SH) clarified that its subsidiary's sales revenue from products used in solid-state battery production is less than 1% of total revenue, emphasizing its focus on quality service [5] - Company Changshan Pharmaceutical (300255.SZ) announced that its application for the marketing authorization of Aibennapeptide injection for type 2 diabetes has been accepted, but the approval timeline remains uncertain [6] Group 3 - Company Baili Electric (600468.SH) reported that its revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue [7] - Company Chutianlong (003040.SZ) is exploring digital currency projects but faces risks related to new technology development and commercial application [8] - Company Dongxing Medical (301290.SZ) signed contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan, enhancing its R&D capabilities [9] Group 4 - Company Maixinlin (688685.SH) announced that its subsidiary signed contracts for computing power services worth 1.184 billion yuan, expected to positively impact future performance [10] - Company Haichen Pharmaceutical (300584.SZ) reported that its solid-state battery-related business has not yet generated revenue, which does not significantly affect overall performance [11] - Company Filinger (603226.SH) is undergoing stock trading suspension for investigation due to significant price deviations from fundamentals [12] Group 5 - Company Zhongdian Port (001287.SZ) disclosed that the National Integrated Circuit Fund reduced its stake by 1%, now holding 8.97% of the company [13] - Company Huasheng Co., Ltd. (600156.SH) is planning to acquire 100% of Yixin Technology, leading to a stock suspension for up to 10 trading days [14] - Company Jianghuai Automobile reported a 3.52% year-on-year decline in May sales, with new energy vehicle sales down 57.81% [15] - Company Aonong Biological reported a 9.44% year-on-year increase in May pig sales, with a total of 156,200 pigs sold [16]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：301290 证券简称：东星医疗 公告编号：2025-024 江苏东星智慧医疗科技股份有限公司 关于控股子公司与上海交通大学 签订技术开发（委托）合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，江苏东星智慧医疗科技股份有限公司（以下简称"公司"）控股子公 司常州东星生物医药有限公司（以下简称"东星生物"）与上海交通大学签订了 《技术开发（委托）合同》，现将相关情况公告如下： 为进一步深化公司产业布局，东星生物与上海交通大学签订了《技术开发（委 托）合同》，合同总金额共计 600 万元。通过本次校企联合，充分利用企业和高 等院校的互补资源，推动科研成果产业化，丰富公司产品模块，提升公司核心竞 争力。 6、上海交通大学简介：上海交通大学是教育部直属并与上海市共建的全国 重点大学，位列国家"双一流"、"985 工程"、"211 工程"重点建设高校， 是中国顶尖、享誉国际的研究型大学，拥有微生物代谢国家重点实验室等多个国 家级重点实验室及前沿交叉平台。 7、实施团队简介：本次项目将由中国科学院院士、上海交通大学生命科学 技术学院名誉院长和微 ...

Company Overview - Dongxing Medical closed at 24.09 yuan on May 20, with an increase of 1.52%, resulting in a rolling PE ratio of 26.93 times and a total market value of 2.413 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times [1] Financial Performance - For Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Capital Flow - On May 20, the net inflow of main funds into Dongxing Medical was 1.2033 million yuan, with a total inflow of 11.8631 million yuan over the past five days [1]

Company Overview - Dongxing Medical's closing price on May 14 was 24.49 yuan, an increase of 2.08%, with a rolling PE ratio of 27.38, marking a new low in 37 days, and a total market capitalization of 2.453 billion yuan [1] - The company specializes in the research, production, and sales of surgical medical devices, with main products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Shareholder Information - As of May 9, 2025, Dongxing Medical had 10,593 shareholders, a decrease of 35 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 49.84, with a median of 36.65, placing Dongxing Medical at the 61st position in the industry ranking [2]

证券代码：301290 证券简称：东星医疗 公告编号：2025-021 江苏东星智慧医疗科技股份有限公司 关于关联方受让控股子公司少数股东股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易事项概述 （一）关联交易基本情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于 2024 年 9 月 18 日召开第四届董事会第四次会议及第四届监事会第四次会议，审议通过了《关 于投资设立控股子公司暨关联交易的议案》，为促进公司长远发展，进一步完善 公司产业布局、提升综合竞争力，在不影响公司日常经营和发展及有效控制投资 风险的前提下，公司拟与控股股东、实际控制人万世平先生及其直接控制的常州 国星投资管理有限公司、实际控制人兼董事、副总经理万正元先生、董事兼总经 理魏建刚先生、董事兼副总经理、董事会秘书、财务总监龚爱琴女士及非关联方 海乐女士共同出资设立常州东星生物医药有限公司（以下简称"东星生物"）， 具体内容详见公司于 2024 年 9 月 18 日披露在巨潮资讯网（www.cninfo.com.cn） 的《关于投资设立控股子公司暨 ...

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 方海乐女士所持有的东星生物 6%股权。鉴于海乐女士尚未出资实缴，故本次股 权转让对价为人民币 0 元。关联董事万世平先生、万正元先生就该事项已回避 表决。 关联方受让控股子公司少数股东股权暨关联交易的 核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐人"）作为 江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"或"公司"）首 次公开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市 保荐业务管理办法》《深圳证券交易所创业板股票上市规则》及《深圳证券交 易所上市公司自律监管指第2号——创业板上市公司规范运作》等相关法律法规、 规范性文件的要求，对东星医疗本次关联方受让控股子公司少数股东股权暨关 联交易的事项进行了审慎核查，并发表本核查意见，具体情况如下： 一、关联交易事项概述 （一）关联交易基本情况 公司于 2024 年 9 月 18 日召开了第四届董事会第四次会议及第四届监事会 第四次会议，审议通过了《关于投资设立控股子公司暨关联交易的议案》，为 促进公司长远发展，进一步完善公司产业布局、提升综合竞争力，在不影响公 ...